Inhibition of c-Jun NH(2)-terminal kinase or extracellular signal-regulated kinase improves lung injury by Lee, Hui Su et al.
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
Respiratory Research
Open Access Research
Inhibition of c-Jun NH2-terminal kinase or extracellular 
signal-regulated kinase improves lung injury
Hui Su Lee1, Hee Jae Kim1, Chang Sook Moon1, Young Hae Chong2 and 
Jihee Lee Kang*1
Address: 1Department of Physiology, Division of Cell Biology, Ewha Medical Research Institute, Ewha Womans University College of Medicine, 
911-1 Mok-6-dong, Yangcheon-ku, Seoul 158-056, Korea and 2Department of Microbiology, Division of Cell Biology, Ewha Medical Research 
Institute, Ewha Womans University College of Medicine, 911-1 Mok-6-dong, Yangcheon-ku, Seoul 158-056, Korea
Email: Hui Su Lee - huisulee@hanmail.com; Hee Jae Kim - kitty7808@hanmail.net; Chang Sook Moon - 94cmoon@hanmail.net; 
Young Hae Chong - younghae@ewha.ac.kr; Jihee Lee Kang* - jihee@ewha.ac.kr
* Corresponding author    
JNKERKLPSacute lung injuryNF-κB
Abstract
Background: Although in vitro studies have determined that the activation of mitogen-activated
protein (MAP) kinases is crucial to the activation of transcription factors and regulation of the
production of proinflammatory mediators, the roles of c-Jun NH2-terminal kinase (JNK) and
extracellular signal-regulated kinase (ERK) in acute lung injury have not been elucidated.
Methods:  Saline or lipopolysaccharide (LPS, 6 mg/kg of body weight) was administered
intratracheally with a 1-hour pretreatment with SP600125 (a JNK inhibitor; 30 mg/kg, IO), or
PD98059 (an MEK/ERK inhibitor; 30 mg/kg, IO). Rats were sacrificed 4 hours after LPS treatment.
Results: SP600125 or PD98059 inhibited LPS-induced phosphorylation of JNK and ERK, total
protein and LDH activity in BAL fluid, and neutrophil influx into the lungs. In addition, these MAP
kinase inhibitors substantially reduced LPS-induced production of inflammatory mediators, such as
CINC, MMP-9, and nitric oxide. Inhibition of JNK correlated with suppression of NF-κB activation
through downregulation of phosphorylation and degradation of IκB-α, while ERK inhibition only
slightly influenced the NF-κB pathway.
Conclusion: JNK and ERK play pivotal roles in LPS-induced acute lung injury. Therefore, inhibition
of JNK or ERK activity has potential as an effective therapeutic strategy in interventions of
inflammatory cascade-associated lung injury.
Background
Lipopolysaccharide (LPS) causes acute lung injury associ-
ated with the activation of macrophages, an increase in
alveolar-capillary permeability, neutrophil influx into the
lungs, and parenchymal injury [1]. This pulmonary
response contributes to the pathogenesis of various acute
inflammatory respiratory diseases. Mitogen-activated pro-
tein (MAP) kinases are crucial in intracellular signal trans-
duction, mediating cell responses to a variety of
inflammatory stimuli, such as LPS, tumor necrosis factor
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(TNF) and interleukin (IL)-1. Recently, various in vitro
studies have shown that pharmacological inhibitors of
MAP kinases strongly affect the production of inflamma-
tory mediators [2,3]. Through the use of specific inhibi-
tors, the potential role of these kinases in inflammatory
lung diseases is beginning to be studied. Treatment with
p38 MAP Kinase inhibitors has been proposed as a selec-
tive intervention to reduce LPS-induced lung inflamma-
tion due to decreases in neutrophil recruitment to the air
spaces [4,5]. However, the functions of c-Jun NH2-termi-
nal kinase (JNK) and extracellular signal-regulated kinase
(ERK) in LPS-induced lung injury remain unclear.
Cytokine-induced neutrophil chemoattractant (CINC)
has been shown, in rodent models of lung injury, to play
an important role in neutrophil migration into the lung
[6]. Matrix metalloproteinases (MMPs), including MMP-
9, allow activated neutrophils to permeate subsequent
extracellular matrix (ECM) barriers after adhesion, and
also for transendothelial cell migration, since these prote-
olytic enzymes digest most of the ECM components in the
basement membranes and tissue stroma [7]. Another
inflammatory mediator, nitric oxide (NO), has been
linked to a number of physiologic processes, including
leukocyte-dependent inflammatory processes and oxi-
dant-mediated tissue injury [8,9]. Like CINC and MMP-9,
overproduction of NO, which is dependent on the activity
of inducible NO synthase, has been reported to contribute
to endothelial or parenchymal injury, as well as to induce
an increase in microvascular permeability, resulting in
lung injury [10,11]. These inflammatory mediators are
produced in response to LPS, TNF and IL-1 [6,11] and are
regulated at the transcription level by nuclear factor-kappa
B (NF-κB) [6,12].
NF-κB activation is regulated by phosphorylation of the
inhibitor protein, IκB-α, which dissociates from NF-κB in
the cytoplasm. The active NF-κB can then translocate to
the nucleus, where it binds to the NF-κB motif of a gene
promoter and functions as a transcriptional regulator. In
vivo activation of NF-κB, but not other transcription fac-
tors, has also been demonstrated in alveolar macrophages
from patients with acute respiratory distress syndrome
(ARDS) [13]. Our previous study indicated that NF-κB
activation is an important mechanism underlying both
LPS-induced NO production, and also MMP-9 activity
and resulting neutrophil recruitment [14]. Therefore, the
activation of NF-κB binding to various gene promoter
regions appears to be a key molecular event in the initia-
tion of LPS-induced pulmonary disease.
Once activated, MAP kinases appear to be capable of fur-
ther signal transduction through kinase phosphorylation,
as well as modulating phosphorylation of transcription
factors [15-17]. Activator protein (AP)-1, another tran-
scription factor mediating acute inflammation, is acti-
vated through MAP kinase signaling cascades in response
to various factors, such as LPS, cytokines, and various
stresses and in turn regulates genes encoding inflamma-
tory cytokines, such as TNF-α, IL-1, IL-6, and IL-8 [18].
Davis [19] reported that activated JNK is capable of bind-
ing the NH2-terminal activation domain of c-Jun, activat-
ing AP-1 by phosphorylating its component c-Jun. AP-1
can then translocate into the nucleus to promote tran-
scription of downstream genes. However, action of MAP
kinases on the upstream of NF-κB activation remains con-
troversial [20-22]. Here, using a selective JNK inhibitor,
SP600125, and the downstream MEK inhibitor of ERK,
PD98059, we focused on the roles of JNK and ERK in LPS-
induced acute lung injury and production of CINC, MMP-
9, and NO. In addition, we investigated the regulatory
effects of these MAP kinases on the NF-κB activation path-
way during acute lung injury.
Methods
Experimental Animals
Specific pathogen-free male Sprague-Dawley rats (280–
300 g) were purchased from Daehan Biolink Co. (Eum-
sung-Gun, Chungbuk, Korea). The Animal Care Commit-
tee of the Ewha Medical Research Institute approved the
experimental protocol. The rats were cared for and han-
dled according to the National Institute of Health (NIH)
Guide for the Care and Use of Laboratory Animals.
Experimental Protocols
Six groups of specific pathogen-free male Sprague-Dawley
rats (280–300 g) were used: (1) controls received an
intratracheal (IT) instillation of 0.5 ml of LPS-free saline
(0.9 % NaCl); (2) an LPS-treated group received an IT
instillation of 6 mg/kg body weight of LPS (Escherichia coli
lipopolysaccharide, 055:B5, Sigma Chemical Co., St.
Louis, MO) in 0.5 ml LPS-free saline; (3) an LPS-
SP600125 group was injected with SP600125 (Calbio-
chem, La Jolla, CA) 1 hour before the IT instillation of 6
mg/kg body weight of LPS in 0.5 ml of LPS-free saline. (4)
a saline-SP600125 group was injected with SP600125 1
hour before IT instillation of 0.5 ml of LPS-free saline (0.9
% NaCl); (5) an LPS-PD98059 group was injected with
PD98059 (BIOMOL Research Laboratories, Plymouth,
PA) 1 hour before IT instillation of 6 mg/kg body weight
of LPS in 0.5 ml of LPS-free saline. (6) a saline-PD98059
group was injected with PD98059 1 hour before IT instil-
lation of 0.5 ml of LPS-free saline (0.9 % NaCl).
SP600125 or PD98059 was injected intraorally via a size
8 French feeding tube at a dose of 30 mg/kg body weight
[5,23]. For IT instillation, rats were treated with enflurane
anesthesia. The trachea was then exposed after a 1 cm
midline cervical incision, and LPS or saline was injected
intratracheally through a 24-gauge catheter. LPS or saline
administration was immediately followed by 3Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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insufflations of 1 ml of air through the catheter and by
rotating the animals to attempt to homogeneously distrib-
ute LPS or saline in the lungs. After a few minutes, the rats
recovered from the anesthesia and were immediately
placed in a chamber. Animals were sacrificed 4 hours after
LPS treatment, and the following parameters were moni-
tored: (1) phosphorylation of JNK, ERK, and p38 MAP
kinase in lung tissue; (2) cell differential count, and meas-
urement of protein content and lactate dehydrogenase
(LDH) activity in bronchoalveolar lavage (BAL) fluid; (3)
cytokine-induced neutrophil chemoattractant (CINC)
expression, matrix metalloproteinase (MMP)-9 activity or
expression and nitrite production in lung tissue, BAL fluid
or the supernatants of alveolar macrophage cultures; (4)
DNA binding activity of nuclear factor-kappa B (NF-κB) in
lung tissue and alveolar macrophages; (5) serine phos-
phorylation and degradation of IκB-α in lung tissue. In
addition, phosphorylation of JNK and ERK was also deter-
mined at 2, 4, 14 or 24 hours after LPS treatment to deter-
mine the kinetics of the kinase activation in lung tissue.
Isolation of BAL cells, Lung Tissue, and Cell Counts
Four hours after LPS treatment, the rats were sacrificed,
and BAL was then performed through a tracheal cannula
with aliquots of 8 ml each using ice-cold Ca2+/Mg2+-free
phosphate-buffered medium (145 mM NaCl, 5 mM KCl,
1.9 mM NaH2PO4, 9.35 mM Na2HPO4, and 5.5 mM dex-
trose; pH 7.4) for a total of 80 ml for each rat. The bron-
choalveolar lavagate was centrifuged at 500 × g for 5 min
at 4°C and cell pellets washed and resuspended in phos-
phate-buffered medium. Cell counts and differentials
were determined using an electronic coulter counter with
a cell sizing analyzer (Coulter Model ZBI with a chan-
nelizer 256; Coulter Electronics, Bedfordshire, UK), as
described by Lane and Mehta [24]. Red blood cells, lym-
phocytes, neutrophils, and alveolar macrophages were
distinguished by their characteristic cell volumes [25]. The
recovered cells were 98% viable, as determined by trypan
blue dye exclusion. Following lavage, lung tissue was
removed, immediately frozen in liquid nitrogen, and
stored at -70°C.
Measurement of Total Protein and lactate dehydrogenase 
(LDH) Activity
To assess the permeability of the bronchoalveolar-capil-
lary barrier, total protein was measured according to the
method of Hartree [26], using bovine serum albumin as
the standard. Total protein and LDH activity were meas-
ured in the first aliquot of the acellular BAL fluid. LDH
activity, a cytosolic enzyme used as a marker for cytotox-
icity, was measured at 490 nm using an LDH determina-
tion kit according to the manufacturer's instructions
(Roche Molecular Biochemicals, Mannheim, Germany).
LDH activity was expressed as U/L, using an LDH
standard.
Western Blot Analysis
Lung tissue homogenate samples (55 µg or 100 µg pro-
tein/lane for JNK, ERK, p38 MAP kinase, IκB-α and CINC)
or aliquots of acellular BAL fluid (70 µl/lane for CINC and
MMP-9) were separated on a 10% or 20% SDS-polyacry-
lamide gel. Separated proteins were electrophoretically
transferred onto nitrocellulose paper and blocked for 1
hour at room temperature with Tris-buffered SAL contain-
ing 3% BSA. The membranes were then incubated with an
anti-rabbit phospho-JNK/JNK antibody, anti-rabbit phos-
pho-ERK/ERK, anti-rabbit phospho-p38 MAP kinase/p38
MAP kinase, antiserum against rat CINC, anti-human
MMP-9 monoclonal antibody or anti-rabbit phospho-
IκBα (Ser32)/IκBα at room temperature for 1 hour. Anti-
body labeling of protein bands was detected with
enhanced chemiluminescence (ECL) reagents according
to the supplier's protocol.
Zymographic Analysis of MMP-9
The gelatinolytic activities in BAL fluid, or the superna-
tants of alveolar macrophage cultures, were determined
using zymography with gelatin copolymerized with acry-
lamide in the gel according to previously published meth-
ods [14]. To obtain the supernatants of alveolar
macrophage cultures, lavage cells were resuspended in
RPMI-1640 medium (Mediatech, Washington, DC), con-
taining 2 mM glutamine, 100 units/ml mycostatin with-
out fetal bovine serum (FBS). Aliquots of 1 ml, containing
106 alveolar macrophages, were added to 24-well plates
(Costar, Cambridge, MA) and incubated at 37°C in a
humidified atmosphere of 5% CO2 for 2 hours. The non-
adherent cells were then removed, and adherent cells were
counted and further incubated in 1 ml RPMI medium.
After a 24 hour incubation, the supernatant was collected
and filtered.
Aliquots of BAL fluid and the culture supernatants, nor-
malized for equal volume (8 µl) or amount of protein (8
µg), were electrophoresed on a 10% SDS-PAGE gel with
0.1% gelatin as a substrate without boiling under non-
reducing conditions. After removing SDS with 2.5% Tri-
ton X-100 for 2 hours, gels were incubated for 20 hours at
37°C in 50 mM Tris-Cl (pH 7.4) containing 10 mM CaCl2
and 0.02% NaN3. The gels were then stained for 1 hour in
7.5% acetic acid/10% propanol-2 containing 0.5%
Coomassie Brilliant Blue G250 and destained in same
solution without dye. Positions of gelatinolytic activity are
unstained on a darkly stained background. The clear
bands on the zymograms were photographed on the neg-
ative (Polaroid's 665 film) and the signals were quantified
by densitometric scanning using an UltroScan XL laser
densitometer (LKB, Model 2222-020) to determine the
intensity of MMP-9 activity as arbitrary densitometric
units. To confirm MMP-9 activity, aliquots of BAL fluid
were analyzed by Western blotting with anti-humanRespiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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MMP-9 monoclonal antibody, which was raised against
MMP-9 secreted by human HT1080 fibrosarcoma cells
[27] and cross-reacts with rat MMP-9 [28].
Nitrite Assay in BAL fluid and Alveolar Macrophage 
Culture
NO levels in the first aliquot of the acellular BAL fluid,
and the supernatants of alveolar macrophage cultures,
were measured using a nitrite assay. Direct measurement
of NO is difficult due to the very short half-life [29]. How-
ever, the stable oxidation end product of NO production,
nitrite, can be readily measured in biological fluids and
has been used in vitro and in vivo as an indicator of NO
production [30]. Briefly, lavage cells were resuspended in
RPMI-1640 medium (Mediatech, Washington, DC), con-
taining 2 mM glutamine, 100 units/ml mycostatin, and
10% FBS. Aliquots of 1 ml, containing 106 alveolar mac-
rophages were added to 24-well plates (Costar, Cam-
bridge, MA) and incubated at 37°C in a humidified
atmosphere of 5% CO2 for 2 hours. The non-adherent
cells were then removed by vigorous washing with two 1
ml of RPMI medium. After incubating the cells for 24
hours, the supernatant was collected and filtered.
Nitrite was assayed after adding 100 µl Greiss reagent (1%
sulfanilamide and 0.1% naphthylethylenediamide in 5%
phosphoric acid) to 50 µl samples of BAL fluid and cell
culture. Optical density at 550 nm (OD550) was measured
using a microplate reader. Nitrite concentrations were cal-
culated by comparison with OD550 of standard solutions
of sodium nitrite prepared in cell culture medium. Data
were presented as µM of nitrite.
Nuclear Extracts
Nuclear extracts were prepared by a modified method of
Sun et al. [31]. Lavage cells were resuspended in Dul-
becco's modified Eagle's medium (DMEM; Mediatech,
Washington, DC), supplemented with 5% FBS (HyClone,
Logan, UT), 2 mM glutamine, and 1,000 units/ml penicil-
lin-streptomycin. DMEM medium (5 ml), containing 5 ×
106 alveolar macrophages, was added to 6-well plates and
incubated at 37°C, in a humidified atmosphere of 5%
CO2  for 2 hours. The nonadherent cells were then
removed with two 1 ml aliquots of DMEM. At the end of
the incubation, adherent cells (> 95% alveolar macro-
phages) were harvested and then resuspended in hypot-
onic buffer A (100 mM HEPES, pH 7.9, 10 mM KCl, 0.1
M ethylenediaminetetraacetic acid [EDTA], 0.5 mM dithi-
othreitol [DTT], 1% Nonidet P-40, and 0.5 mM phenyl-
methylsulfonyl fluoride [PMSF]) for 10 min on ice, then
vortexed for 10 s. Nuclei were pelleted by centrifugation at
12,000 rpm for 30 s. Nuclear extracts were also prepared
from lung tissue by the modified method of Deryckere
and Gannon [32]. Aliquots of frozen tissue were mixed
with liquid nitrogen and ground to powder using a mortar
and pestle. The ground tissue was placed in a Dounce tis-
sue homogenizer (Kontes Co., Vineland, NJ) in the pres-
ence of 4 ml of buffer A to lyse the cells. The supernatant
containing intact nuclei was incubated on ice for 5 min,
and centrifuged for 10 min at 5,000 rpm. Nuclear pellets
obtained from alveolar macrophages or lung tissue were
resuspended in buffer C (20 mM HEPES, pH 7.9, 20%
glycerol, 0.42 M NaCl, 1 mM EDTA, and 0.5 mM PMSF)
for 30 min on ice. The supernatants containing nuclear
proteins were collected by centrifugation at 10,000 rpm
for 2 min, and stored at -70°C.
Electrophoretic Mobility Shift Assay (EMSA)
Binding reaction mixtures (10 µl), containing 5 µg (4 µl)
nuclear extract protein, 2 µg poly (dI-dC)•poly (dI-dC)
(Sigma Co., St. Louis. MO), and 40,000 cpm 32P-labeled
probe in binding buffer (4 mM HEPES, pH 7.9, 1 mM
MgCl2, 0.5 mM DTT, 2% glycerol, and 20 mM NaCl), were
incubated for 30 min at room temperature. The protein-
DNA complexes were separated on 5% non-denaturing
polyacrylamide gels in 1 × TBE buffer, and autoradio-
graphed. Autoradiographic signals for activated NF-κB
were quantitated by densitometric scanning using an
UltroScan XL laser densitometer (LKB, Model 2222-020,
Bromma, Sweden) to determine the intensity of each
band.
The oligonucleotide used as a probe for EMSA was a dou-
ble-stranded DNA fragment, containing the NF-κB con-
sensus sequence (5'-
CCTGTGCTCCGGGAATTTCCCTGGCC-3'), labeled with
[α-32P]-dATP (Amersham, Buckinghamshire, UK), using
DNA polymerase Klenow fragment (Life Technologies,
Gaithersburg, MD). Cold competition was performed by
adding 100 ng unlabeled double-stranded probe to the
reaction mixture.
Statistical Analysis
Values were expressed as means ± standard errors. Data
were compared among the groups by one-way ANOVA
followed by a Tukey's post hoc test. A P value of < 0.05 was
considered to be statistically significant.
Results
Phosphorylation of JNK and ERK in Lung Tissue
To determine JNK and ERK activation in the lung tissue
from LPS treated animals, Western blot analysis with a
phospho-specific JNK antibody or ERK antibody was
employed. Figures 1A and 1B showed time courses of LPS-
induced phosphorylation, or activation, of JNK1/2 and
ERK1/2. Phosphorylation of these MAP kinases substan-
tially increased beginning 4 hours after LPS treatment,
and progressively further increased (JNK activation) or
were maintained (ERK activation) for up to 24 hours after
LPS treatment. SP600125 pretreatment partially inhibitedRespiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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LPS-induced phosphorylation of JNK1/2 in lung tissue at
4 hours after LPS treatment (Figure 2A), but this inhibitor
had little effect on the activation of ERK1/2 (2C) and p38
MAP kinse (2E). PD98059 pretreatment specifically
inhibited the activation of ERK1/2 (Figure 2D), but nei-
ther the activation of JNK1/2 (2B) nor p38 MAP kinase
(2F). Both JNK and ERK activation were barely detectable
in the animals treated with saline or saline-kinase
inhibitors.
Total Protein and LDH Activity in BAL Fluid and 
Neutrophil Influx into Lungs
BAL protein contents (Figure 3A) and LDH activity (Figure
3B) in LPS-treated animals were significantly increased (p
< 0.05). BAL protein increased 2.9-fold, and LDH activity
increased 4.7-fold. This indicates that IT LPS treatment of
rats induced acute lung injury. However, SP600125 or
PD98059 pretreatment significantly inhibited LPS-
induced changes in protein contents, by 63 and 74%,
respectively, and BAL LDH activity by 71 and 86%, respec-
tively (P < 0.05). There were no significant differences in
these parameters between saline-SP600125, saline-
PD98059, and saline control animals (p < 0.05).
BAL cells were differentially analyzed, in order to evaluate
the effects of these kinase inhibitors on LPS-induced neu-
trophil influx. As shown in Figure 3C, neutrophil counts
of the total lung lavage cells in LPS-treated animals signif-
icantly increased by a factor of 26, compared to values in
saline-treated animals, indicating a significant increase in
neutrophil influx into the alveolar spaces (p < 0.05).
SP600125 or PD98059 significantly suppressed BAL neu-
trophil counts by 53 or 46 %, respectively (vs LPS animals,
p < 0.05). The BAL neutrophil counts in saline-kinase
inhibitor animals were not significantly different from
those of the saline control animals (p < 0.05).
CINC, MMP-9 and NO Production in Lungs or Alveolar 
Macrophages
CINC, MMP-9 and NO were chosen in our experiments as
representative inflammatory mediators, because of their
important roles in neutrophil influx and lung damage,
and also because their gene regulation is dependent on
NF-κB. Figure 4 illustrates representative Western blots of
lung tissue and BAL fluid for CINC. CINC protein expres-
sion was undetectable in the samples of saline control ani-
mals, but was markedly increased by LPS treatment for 4
hours. By densitometric analysis, CINC protein in lung
tissue (Figure 4A and 4Clane 2) and BAL fluid (Figure 4B
and 4Dlane 2) from LPS animals was approximately 7-
and 2.5-fold higher than in saline control animals, respec-
tively. SP600125 or PD98059 significantly decreased the
level of LPS-induced CINC expression, by 50 and 62%,
respectively, in lung tissue (Figure 4A and 4Clane 3, p <
0.05) and, by 76 and 97%, respectively, in BAL fluid (Fig-
ure 4B and 4Dlane 3, p < 0.05). These kinase inhibitors
alone had little effect on CINC levels in the lung tissue
and lavage fluid.
BAL fluid (Figure 5A and 5D), and the supernatants from
alveolar macrophage cultures (Figure 5B and 5E), were
analyzed for evidence of MMP-9 activity, using gelatin
zymography. The BAL fluid from the saline control ani-
mals showed undetectable gelatinolytic bands. LPS treat-
ment induced a distinct increase in the amount of
gelatinolytic activity and the most prominent band was
found to be a 92 kD species in the BAL fluid, correspond-
ing to a molecular weight identical to MMP-9 [25,26].
This was confirmed to be MMP-9 by Western blot analysis
with the antiMMP-9 monoclonal antibody (Figure 5C and
5Flane 2). In the supernatants from alveolar macrophage
cultures of saline control animals, MMP-9 activity was
also barely detectable, but was also markedly increased in
Time course of phosphorylation of JNK (A) and ERK (B), in lung tissue from rats treated with saline (0 time) or LPS (2–24 h) Figure 1
Time course of phosphorylation of JNK (A) and ERK (B), in lung tissue from rats treated with saline (0 time) or LPS (2–24 h). 
Western blots with anti-phospho-JNK/JNK antibody or phospho-ERK/ERK antibody were employed in order to monitor JNK 
or ERK phosphorylation. Relative values for levels of phosphorylated JNK1/2 or ERK1/2 normalized to JNK1/2 or ERK1/2 are 
indicated below the gel. Results are representative results from 5 rats in each group.Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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Phosphorylation of JNK (A, B), ERK (C, D)and p38 MAP kinase (E, F) in lung tissue 4 hours after saline or LPS treatment Figure 2
Phosphorylation of JNK (A, B), ERK (C, D)and p38 MAP kinase (E, F) in lung tissue 4 hours after saline or LPS treatment. The 
groups represent rats treated as follows: Saline, saline (IT); LPS, LPS (IT); LPS-SP600125, LPS (IT) and a pretreatment with 
SP600125 (IO), Saline-SP600125, saline (IT) and a pretreatment with SP600125 (IO);LPS-PD98059, LPS (IT) and a pretreatment 
with PD98059 (IO), Saline-PD98059, saline (IT) and a pretreatment with PD98059 (IO). Western blots with anti-phospho-
JNK/JNK antibody, phospho-ERK/ERK antibody or phospho-p38 MAP kinase/p38 MAP kinase were employed in order to mon-
itor JNK, ERK or p38 MAP kinase phosphorylation. Relative values for levels of phosphorylated JNK1/2, ERK1/2 or p38 MAP 
kinse normalized to JNK1/2, ERK1/2 or p38 MAP kinase are indicated below the gel. Results are representative results from 5 
rats in each group.Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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the sample from LPS animals. SP600125 pretreatment sig-
nificantly inhibited LPS-induced MMP-9 activity by 54%
in BAL fluid, and by 30% in the supernatants from alveo-
lar macrophage cultures (Figure 5A and 5Blane 3, p <
0.05). Similarly, PD98059 pretreatment significantly
inhibited LPS-induced MMP-9 activity by approximately
67% in BAL fluid and the supernatants from alveolar mac-
rophage cultures (Figure 5D and 5Elane 3, p < 0.05).
MMP-9 activity was completely undetectable in the sam-
ples from saline-kinase inhibitor animals. The inhibitory
effect of these kinase inhibitors on MMP-9 expression in
BAL fluid was also observed (Figure 5C and 5Flane 3).
NO levels in BAL fluid and alveolar macrophages in cul-
ture were determined by measurement of nitrite in their
supernatants. Figure 6A illustrates that in vivo exposure to
LPS for 4 hours resulted in a 6.2-fold increase in NO level
in BAL fluid, compared with the control animals. This
increase was significantly inhibited by SP600125 or
PD98059 (69% and 81% inhibition, respectively, p <
0.05, vs LPS animals). In LPS treated animals, nitrite pro-
duction from alveolar macrophages cultured for 24 hours
was increased 3.2-fold (Figure 6B). SP600125 or PD
98059 significantly suppressed LPS-induced NO produc-
tion by alveolar macrophages by 89 and 58%, respectively
(p < 0.05). NO level was only slightly changed in the sam-
ples from saline-kinase inhibitor animals.
NF-κB Activation in Lung Tissue and Alveolar 
Macrophages
Figure 7 shows NF-κB activation in lung tissue and alveo-
lar macrophages, identified 4 hours after IT instillation of
saline or LPS. In LPS-treated animals, the DNA-binding
activities of NF-κB in lung tissue were markedly enhanced
(Figure 7A and 7Clane 2). This enhancement was signifi-
cantly depressed (67% inhibition, p < 0.05, vs LPS ani-
mals) by a 1-hour pretreatment with SP600125 (Figure
7Alane 3), whereas pretreatment with PD98059 did not
inhibit LPS-induced activation of NF-κB (7C lane 3). Sig-
nificant activation of NF-κB was also shown in alveolar
macrophages from LPS-treated animals, compared to that
seen in the saline control animals (Figure 7B and 7Dlane
2, p < 0.05). SP600125 resulted in significant decreases
(45%, p < 0.05) in LPS-induced NF-κB activation in alve-
olar macrophages (Figure 7Blane 3). However, PD98059
did not inhibit LPS-induced NF-κB activation in alveolar
macrophages (Figure 7Dlane 3). Saline or kinase inhibi-
tors alone had little effect on NF-κB activation in lung tis-
sue and alveolar macrophages.
The addition of the cold competitor eliminated the spe-
cific bands in the samples from LPS-treated animals, indi-
cating that the band on the autoradiogram was specific for
NF-κB binding (Figure 7A,7B,7C and 7Dlane 5).
Levels of total protein (A), activity of LDH (B) and neutrophil  numbers (C) in bronchoalveolar lavage fluid Figure 3
Levels of total protein (A), activity of LDH (B) and neutrophil 
numbers (C) in bronchoalveolar lavage fluid. The groups rep-
resent rats treated as follows: Saline, saline (IT); LPS, LPS 
(IT); LPS-SP600125, LPS (IT) and a pretreatment with 
SP600125 (IO), Saline-SP600125, saline (IT) and a pretreat-
ment with SP600125 (IO);LPS-PD98059, LPS (IT) and a pre-
treatment with PD98059 (IO), Saline-PD98059, saline (IT) 
and a pretreatment with PD98059 (IO). Animals were sacri-
ficed 4 hours after LPS treatment. Values represent means ± 
SEM of results from 5 rats in each group. * Significant differ-
ences between saline, p < 0.05, and + significant difference 
compared with LPS group, p < 0.05.Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
Page 8 of 15
(page number not for citation purposes)
CINC expression in lung tissue (A, C) and bronchoalveolar lavage fluid (B, D) Figure 4
CINC expression in lung tissue (A, C) and bronchoalveolar lavage fluid (B, D). The groups represent rats treated as follows: 
The groups represent rats treated as follows: Saline, saline (IT); LPS, LPS (IT); LPS-SP600125, LPS (IT) and a pretreatment with 
SP600125(IO), Saline-SP600125, saline (IT) and a pretreatment with SP600125(IO); LPS-PD98059, LPS (IT) and a pretreatment 
with PD98059 (IO), Saline-PD98059, saline (IT) and a pretreatment with PD98059 (IO). Animals were sacrificed 4 hours after 
LPS treatment. Western blots with anti-CINC antibodies were performed on the samples of lung tissue and BAL fluid. Densit-
ometry of CINC bands is expressed in arbitrary densitometric units. Values are represented as means ± SEM of results from 5 
rats in each group. * Significant differences between saline, p < 0.05, and + significant difference compared with LPS group, p < 
0.05.Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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Gelatinolytic activities in bronchoalveolar lavage fluid (A, D) and the supernatants of alveolar macrophages in culture (B, E) Figure 5
Gelatinolytic activities in bronchoalveolar lavage fluid (A, D) and the supernatants of alveolar macrophages in culture (B, E). 
MMP-9 expression in bronchoalveolar lavage fluid (C, F). The groups represent rats treated as follows: Saline, saline (IT); LPS, 
LPS (IT); LPS-SP600125, LPS (IT) and a pretreatment with SP600125(IO), Saline-SP600125, saline (IT) and a pretreatment with 
SP600125 (IO); LPS-PD98059, LPS (IT) and a pretreatment with PD98059 (IO), Saline-PD98059, saline (IT) and a pretreatment 
with PD98059 (IO). Animals were sacrificed 4 hours after LPS treatment. Alveolar macrophages (106/m1 of RPMI medium) 
were incubated for 24 hours. BAL fluid and culture supernatants were analyzed by sensitive zymography, followed by scanning 
densitometry. 92 kD and 66 kD gelatinolytic bands correspond to MMP-9 and MMP-2, respectively. Densitometry of 92 kD 
bands is expressed in arbitrary densitometric units. Western blots of BAL fluid with anti-MMP-9 antibodywere employed to 
monitor MMP-9. Values are represented as means ± SEM of results from 5 rats in each group. * Significant differences between 
saline, p < 0.05, and + significant difference compared with LPS group, p < 0.05.Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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Phosphorylation and Degradation of IκB-α in Lung Tissue
In order to investigate a possible mechanism underlying
the actions of these kinase inhibitors on LPS induction of
pathways leading to NF-κB activation, serine phosphor-
ylation and degradation of IκB-α, in lung tissue from LPS
and LPS-kinase inhibitor animals were analyzed by West-
ern blotting with anti-phospho-IκB-α (serine 32), and
anti-IκB-α Ab. As shown in Figure 8, LPS treatment
resulted in the induction of serine phosphorylation of
IκB-α, and a substantial reduction in IκB-α protein con-
tent in lung tissue (8A and 8C lane 2), whereas these
events were significantly inhibited by SP600125 (8A and
8C  lane 3). PD98059, however, caused no significant
changes in the LPS-induced phosphorylation and degra-
dation of IκB-α (Figure 8B and 8Dlane 3). These kinase
inhibitors, alone, had little effect on the phosphorylation
and degradation of IκB-α.
Discussion
In the present study, we determined: (1) the in vivo rela-
tion between activation of JNK or ERK and LPS-induced
acute lung injury; (2) the inhibition of JNK or ERK
resulted in reductions of LPS-induced increases in lung
injury parameters, such as total protein content and LDH
activity in BAL fluid, neutrophil influx into the lungs, and
proinflammatory gene products, such as CINC, MMP-9
and NO; and (3) the activation of JNK is involved in the
LPS signaling pathway leading to NF-κB activation
through phosphorylation of IκB-α and sequential degra-
dation of IκB-α, whereas activation of ERK signaling is not
associated with these NF-κB pathways.
JNK and ERK are known to play important roles as
upstream regulators of the induced expression of inflam-
matory mediators in response to cytokines, stress, and
cytoskeletal reorganization [19,33]. However, these
results were exclusively obtained during in vitro experi-
ments. Therefore, it is important to clarify the functions of
these MAP kinases under pathological conditions. Fur-
thermore, up to date, there have been no studies address-
ing the issues of the significance of JNK and ERK signaling
in LPS-induced acute lung injury. Data from the present
study clearly indicate that JNK and ERK were both acti-
vated after in vivo LPS exposure in models of acute lung
injury. The degree of JNK and ERK activation from the
baseline seems to be similar between these kinases, and to
be generally higher than that of p38 MAP kinase (data not
shown). The time course of JNK activation (progressive
increase up to 24 hours after LPS treatment) appears to
occur in parallel with those of the biochemical lung injury
variables and neutrophil influx into the lungs after intrat-
racheal treatment with LPS [14]. Consistent with our in
vivo data, Ishii et al. [34] have reported that both JNK and
ERK were simultaneously activated in the lung during
ischemia and reperfusion. To explore a new therapeutic
strategy for preventing the occurrence of LPS-induced lung
inflammation and injury, we attempted to inhibit JNK or
ERK activity by pretreatment with a selective JNK inhibi-
tor, SP600125, or a specific inhibitor of MEK/ERK,
PD98059, 1 hour before LPS treatment. Inhibition of
NO production in BAL fluid (A) and alveolar macrophages in  culture (B) Figure 6
NO production in BAL fluid (A) and alveolar macrophages in 
culture (B). The groups represent rats treated as follows: 
Saline, saline (IT); LPS, LPS (IT); LPS-SP600125, LPS (IT) and a 
pretreatment with SP600125 (IO), Saline-SP600125, saline 
(IT) and a pretreatment with SP600125 (IO); LPS-PD98059, 
LPS (IT) and a pretreatment with PD98059 (IO), Saline-
PD98059, saline (IT) and a pretreatment with PD98059 (IO). 
Animals were sacrificed 4 hours after LPS treatment. Alveo-
lar macrophages (106/m1 of RPMI medium) were incubated 
for 24 hours. BAL fluid and culture supernatants were ana-
lyzed using nitrite assays. Values are represented as means ± 
SEM of results from 5 rats in each group. * Significant differ-
ences compared with saline, p < 0.05, and + significant differ-
ence compared with LPS group, p < 0.05.Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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EMSA illustrating DNA-binding activity of NF-κB to the NF-κB motif in lung tissue (A, C), and alveolar macrophages (B, D) Figure 7
EMSA illustrating DNA-binding activity of NF-κB to the NF-κB motif in lung tissue (A, C), and alveolar macrophages (B, D). 
The groups represent rats treated as follows: Saline, saline (IT); LPS, LPS (IT); LPS-SP600125, LPS (IT) and a pretreatment with 
SP600125 (IO), Saline-SP600125, saline (IT) and a pretreatment with SP600125 (IO); LPS-PD98059, LPS (IT) and a pretreat-
ment with PD98059 (IO), Saline-PD98059, saline (IT) and a pretreatment with PD98059 (IO). Animals were sacrificed 4 hours 
after LPS treatment. Nuclear extracts were prepared in lung tissue and alveolar macrophages (5 × 106 alveolar macrophages). 
Addition of 100 ng of unlabeled cold competitor to the LPS samples successfully competed for NF-κB binding, and eliminated 
the specific band. Densitometry of NF-κB bands on EMSA is expressed in arbitrary densitometric units. Values are represented 
as means ± SEM of results from 5 rats in each group. * Significant differences compared with saline, p < 0.05, and + significant 
difference compared with LPS group, p < 0.05.Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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Phosphorylation (A, B) and degradation (C, D) of IκB-α in lung tissue Figure 8
Phosphorylation (A, B) and degradation (C, D) of IκB-α in lung tissue. The groups represent rats treated as follows: Saline, 
saline (IT); LPS, LPS (IT); LPS-SP600125, LPS (IT) and a pretreatment with SP600125 (IO), Saline-SP600125, saline (IT) and a 
pretreatment with SP600125 (IO); LPS-PD98059, LPS (IT) and a pretreatment with PD98059 (IO), Saline-PD98059, saline (IT) 
and a pretreatment with PD98059 (IO). Animals were sacrificed 4 hours after LPS treatment. Western blots with anti-serine 
phospho-IκBα (Ser32)/IκBα antibody were employed to monitor phosphorylated IκB-α and IκB-α. Densitometry of phospho-
IκB-α/IκB-α bands is expressed in arbitrary densitometric units. Values represent means ± SEM of results from 5 rats in each 
group. * Significant differences compared with saline, p < 0.05, and + significant difference compared with LPS group, p < 0.05.Respiratory Research 2004, 5:23 http://respiratory-research.com/content/5/1/23
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either JNK or ERK activity resulted in reduction of LPS-
induced increases in lung injury parameters, as well as
neutrophil influx into the lungs, indicating that
aggravating signals related to both JNK and ERK are asso-
ciated with LPS-induced acute lung injury.
Since the increases in production or activity of CINC,
MMP-9 and NO in BAL fluid were correlated with neu-
trophil influx and lung injury [6,8,9,11], the inhibitory
effects of JNK or ERK on production of these inflamma-
tory mediators are functionally important, and can thus
be adopted as therapeutic interventions. Recently, it has
been demonstrated that JNK inhibition by SP600125, in
both ischemia and reperfusion periods, almost com-
pletely suppressed TNFα release into BAL fluid [34] and
IL-1-induced MMP expression in synoviocytes and in joint
arthritis [23]. These in vivo data with the specific JNK
inhibitor are clearly consistent with an aggravating role of
JNK in inflammation and tissue destruction. However,
JNK1-/- mice have increased susceptibility to hyperoxia-
induced lung injury [35]. Through in vitro studies of pri-
mary monocytes and macrophage cell lines, ERK has been
linked to production of MMP-9, and to IL-8 release in
response to LPS [36] or Helicobacter pylori [16]. Consistent
with our data with ERK, Zhang et al. [37] reported that
inhibition of ERK by PD98059 in vivo suppressed hyper-
oxia-induced cell death in lung tissues. ERK, however, also
plays a protective role in myocardial ischemia/reperfusion
injury [38], and in myoglobinuric acute renal injury [39].
Taken together, the primary role of JNK or ERK may play
either a protective or injurious role under different exper-
imental conditions.
The activation of NF-κB has been associated with lung
injury in LPS- and silica-treated rats [6,40,41], and
patients with ARDS [42] and asthma [43]. Data from our
previous study indicate that in vivo activation of NF-κB in
LPS-treated rats preceded the transcription of genes for
proinflammatory mediators or lung inflammation and
injury, i.e. the increases in neutrophil numbers, total pro-
tein, and LDH activity in BAL fluid [9]. These results sug-
gest that NF-κB is an important intracellular target for the
early detection and prevention of lung injury. Since the
NF-κB element is believed to be the main regulator of
CINC, MMP-9 and iNOS expression, and MAP kinase
pathways have been demonstrated to contribute to the
activation of NF-κB [15,44,45], we attempted to investi-
gate the action of MAP kinases on the upstream of NF-κB
signal transduction pathways in LPS-induced acute lung
injury. Data from the present study indicate that
inhibition of JNK suppresses LPS-induced increases in the
DNA binding activity of NF-κB, through down-regulation
of phosphorylation and degradation of IκB-α. Recently,
Leonardi et al. [46] have reported that CIKS, a NF-κB
essential modulator (NEMO)/IκB-α kinase (IKK)γβ-asso-
ciated protein, connects to both the IKK and JNK signaling
complexes, and activates an NF-κB-dependent reporter.
Consequently, our and Leonardi et al.'s data support the
possibility of JNK's role as an upstream activator of NF-κB,
although the apparent complexity may reflect the fact that
many diverse signals affect these two pathways. However,
inhibition of ERK did not influence LPS induction of NF-
κB activation, or the phosphorylation and degradation of
IκB-α. The action of MAP kinases on the upstream of NF-
κB pathways remains controversial in the context of in
vitro experiments [20,47-51]. For instance, over-expres-
sion of either MEK1 or ERK1 resulted in a constitutive
nuclear localization of NF-κB DNA binding activity [47].
Conversely, transfection with dominant negative MEK1
suggested that the ERK pathway does not regulate NF-κB
DNA binding, stimulated by Helicobacter pylori [49]. Con-
sidering, by inference, a critical role of NF-κB in the LPS-
induced inflammatory cascade, we speculate that ERK
may exert effects on gene expression of these inflamma-
tory mediators by modulating TATA-binding protein acti-
vation without affecting DNA binding activity [21].
Further study is absolutely necessary, however, to clarify
the pathways of these MAP kinases associated with NF-κB,
as well as other transcription factors, including AP-1 and
cyclic adenosine 5'-monophosphate response element-
binding protein (CREB).
Conclusion
Data from this study suggest that JNK or ERK activation
would play a detrimental role in LPS-induced acute lung
injury. The inhibition of JNK or ERK should effectively
block amplification of the LPS-induced catalytic cascade,
through significant reductions in protein leakage, LDH
release and neutrophil influx into the lung, and also in
levels of CINC, MMP-9 and NO after LPS treatment. In
addition, the inhibition of JNK activity, but not ERK
activity, led to a decrease in NF-κB DNA binding activity
through the suppression of phosphorylation and degrada-
tion of IκB-α. Based on these findings, we propose that
inhibition of JNK or ERK may be an effective therapeutic
strategy against the early stages of lung injury, via attenu-
ation of the inflammatory cascade.
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